Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Sell

Analyst Rating

Sell

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Neutral

Standard Deviation

Neutral

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

Lexicon Pharmaceuticals, Inc. (LXRX)

Pharmaceutical Preparations

https://www.lexpharma.com

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.

2445 TECHNOLOGY FOREST BLVD., SUITE 1100
THE WOODLANDS, TX

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

04/07/2000

Market Cap

605,499,100

Shares Outstanding

244,930,000

Weighted SO

244,024,695

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

BLRX --.--%

ARDX --.--%

MCRB --.--%

IBRX --.--%

EFTR --.--%

XFOR --.--%

ELEV --.--%

MREO --.--%

Beta

1.3570

Last Div

0.0000

Range

0.92-3.73

Chg

0.0350

Avg Vol

2839188

Mkt Cap

605499100

Exch

NASDAQ

Country

US

Phone

281 863 3000

DCF Diff

2.0464

DCF

-0.3914

Div Yield

0.0000

P/S

166.3002

EV Multiple

-3.4891

P/FV

2.1696

Div Yield %

0.0000

P/E

-2.5955

PEG

0.0894

Payout

0.0000

Current Ratio

11.5097

Quick Ratio

11.4887

Cash Ratio

1.2777

DSO

262.6476

DIO

303.3026

Op Cycle

565.9502

DPO

6335.6534

CCC

-5769.7032

Gross Margin

0.8066

Op Margin

-54.1211

Pretax Margin

-55.0934

Net Margin

-55.0934

Eff Tax Rate

0.0001

ROA

-0.5373

ROE

0.7327

ROCE

-0.5704

NI/EBT

1.0000

EBT/EBIT

1.0180

EBIT/Rev

-54.1211

Debt Ratio

0.2700

D/E

0.4200

LT Debt/Cap

0.2931

Total Debt/Cap

0.2958

Int Coverage

-16.3436

CF/Debt

-1.9430

Equity Multi

1.5558

Rec Turnover

1.3897

Pay Turnover

0.0576

Inv Turnover

1.2034

FA Turnover

0.5099

Asset Turnover

0.0098

OCF/Share

-0.6300

FCF/Share

-0.6311

Cash/Share

0.9972

OCF/Sales

-53.7866

FCF/OCF

1.0017

CF Coverage

-1.9430

ST Coverage

-151.6940

CapEx Coverage

-588.0991

Div&CapEx Cov

-588.0991

P/BV

2.1696

P/B

2.1696

P/S

166.3002

P/E

-2.5955

P/FCF

-3.0866

P/OCF

-2.6586

P/CF

-2.6586

PEG

0.0894

P/S

166.3002

EV Multiple

-3.4891

P/FV

2.1696

DPS

0.0000

Latest Headlines (EST)

Benzinga Mar 31, 05:25 While Wall Street Panicked, These 3 Hidden Small-Caps Exploded Last Week — One Surging A Jaw-Dropping 60% GlobeNewswire Inc. Mar 02, 21:13 Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain GlobeNewswire Inc. Oct 31, 22:54 Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease The Motley Fool Jan 23, 05:21 3 of the Fastest-Growing Stocks on the Planet in 2024 The Motley Fool Jan 02, 05:06 7 Magnificent Stocks That Can Double Your Money in 2024 The Motley Fool Dec 26, 05:06 3 Growth Stocks Expected to Skyrocket in 2024, According to Wall Street The Motley Fool Dec 26, 05:06 3 Growth Stocks Expected to Skyrocket in 2024, According to Wall Street GlobeNewswire Inc. Dec 21, 16:15 Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference GlobeNewswire Inc. Nov 30, 07:30 Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) GlobeNewswire Inc. Nov 22, 07:30 Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference GlobeNewswire Inc. Nov 12, 14:10 INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data GlobeNewswire Inc. Nov 12, 14:10 INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data GlobeNewswire Inc. Nov 12, 14:10 INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data GlobeNewswire Inc. Nov 12, 14:10 INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data GlobeNewswire Inc. Nov 12, 14:10 INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data GlobeNewswire Inc. Nov 12, 14:10 INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data GlobeNewswire Inc. Nov 12, 14:10 INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data GlobeNewswire Inc. Nov 12, 14:10 INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data GlobeNewswire Inc. Nov 12, 14:10 INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data GlobeNewswire Inc. Nov 12, 14:10 INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data

Revenue Product Segmentation